Understanding lung cancer in young adults
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
This study is trying to learn more about the causes of lung cancer in young adults under 45 to help improve how we screen and treat this rare condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 4 sites (Boston, Massachusetts and 3 other locations) |
| Trial ID | NCT05265429 on ClinicalTrials.gov |
What this trial studies
This research focuses on individuals diagnosed with lung cancer at age 45 or younger, aiming to gather insights into the causes and risk factors associated with this rare condition. The study will enroll approximately 500 participants and will involve collecting medical records, questionnaires, blood or saliva samples, and optional tumor tissue samples. By examining genetic changes and other factors, the study seeks to improve screening and treatment options for young lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 45 or younger who have been diagnosed with non-small cell lung cancer or small cell lung carcinoma.
Not a fit: Patients diagnosed with lung cancer over the age of 45 or those who decline to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of lung cancer in younger patients.
How similar studies have performed: While studies on lung cancer exist, this specific focus on young adults is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 45 and under at lung cancer diagnosis * Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point * Provision of written informed consent * Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks * Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent Exclusion Criteria: * Individuals who decline to sign consent * Individuals who are unable to give consent or assent and are without a designated healthcare proxy * Compromise of patient diagnosis or staging if tissue is used for research
Where this trial is running
Boston, Massachusetts and 3 other locations
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (Not_yet_recruiting)
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Not_yet_recruiting)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Pasi A Janne, MD, PhD — Dana-Farber Cancer Institute
- Study coordinator: Pasi A Janne, MD, PhD
- Email: Pasi_Janne@dfci.harvard.edu
- Phone: 617-632-6036
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.